Skip to main content
Quest Diagnostics

Cost Effectiveness of Population-Level Preventative Genetic Screening for Underdiagnosed Hereditary Conditions and Implications for Implementation by Health Systems

ACHE 2024 Congress on Healthcare Leadership

American College of Healthcare Executives

Chicago, IL March 25 - 28, 2024

Poster presentation: Cost Effectiveness of Population-Level Preventative Genetic Screening for Underdiagnosed Hereditary Conditions and Implications for Implementation by Health Systems

Authors: Burton RA, South S, Champine M,  Serra R

Specialty: Genetics, Oncology

Related content

Conference Presentation
Cost Savings of Implementing a Higher Validated Dilution of Serum Folate
Publication
Strategies to Drive Effective Laboratory Test Utilization

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA certified laboratories that provide HIPAA covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2024 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.